Identical stool samples sent to seven direct-to-consumer microbiome testing companies produced substantially different ...
VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new ...
VANCOUVER, BC — Two multitarget stool tests in development compare favorably for colorectal cancer (CRC) screening in average-risk people, suggest two new studies. In a blinded, prospective, ...
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...
The results were even more disparate than the team had expected. Of the more than 1,200 families of microbes identified by all the tests combined, just three microbe families were present in all seven ...
A study has used advanced genetic and genomic techniques to offer a major step forward in understanding and diagnosing infectious intestinal diseases. The large-scale study analyzed more than 1,000 ...
Colorectal cancer is highly treatable when caught early—and FIT tests make screening easier than ever with a simple at‑home ...
The FDA has cleared a multiplex polymerase chain reaction test designed to detect 11 clinically relevant gastrointestinal pathogens from a single stool sample.The Xpert GI Panel (Cepheid) can identify ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results